Strive CEO Matt Cole says firm will sell Bitcoin if beneficial for shareholders
Strive's flexible Bitcoin strategy highlights the balance between shareholder value and cryptocurrency volatility, impacting investor confidence. The post Strive CEO Matt Cole says firm will sell Bitcoin if beneficial fo...
Archive context
Older archive item. Useful for background and entity history, but not a fresh market-moving signal.
Strive's flexible Bitcoin strategy highlights the balance between shareholder value and cryptocurrency volatility, impacting investor confidence.
The post Strive CEO Matt Cole says firm will sell Bitcoin if beneficial for shareholders appeared first on Crypto Briefing.
Why this matters
Bitcoin is a tracked market entity in the DigitalMoneyBox archive, making this useful context for readers monitoring repeated mentions and follow-up coverage.
Original source
Read on Crypto BriefingRelated market context
Lite Strategy Funds $5.4M Buyback With Litecoin Sales And Covered Calls
Lite Strategy has repurchased 4.9 million shares for $5.4 million, using Litecoin treasury activity and covered-call premiums to f...
Bitcoin (BTC) Price Today: Michael Saylor’s Strategy Reports $8.3B Loss as BTC Slides Below $64K
The BTC move comes shortly after Strategy reported an $8.33 billion operating loss for the second quarter of 2026, including an $8...
From crypto treasury to AI data centers: Inside the aggressive 4,375 ETH selloff that just hit a massive collateral wall
Japan-listed Quantum Solutions expanded the amount of Ether its group may sell through Oct. 30, 2026, after subsidiary GPT Pals St...
CleanCore’s $800M AI Contract Shows Dogecoin Treasury Firms Are Changing Shape
CleanCore Solutions has signed a 10-year colocation agreement with Cerebras Systems valued at $800 million, and the story is not j...
Strategy’s Saylor confident STRC will hit $100, buybacks may increase
Saylor's confidence and potential buybacks could stabilize STRC's value, impacting investor sentiment and market dynamics signific...
Biotech company asks shareholders to dilute stock by 951% to hoard illiquid crypto token instead of funding its own drug
Enlivex, a Nasdaq-listed biotechnology company, is asking shareholders to authorize up to $800 million of financing tied to the RA...